J
Jernelle Miller
Researcher at Johns Hopkins University School of Medicine
Publications - 10
Citations - 414
Jernelle Miller is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 6, co-authored 8 publications receiving 213 citations. Previous affiliations of Jernelle Miller include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers.
Eshan U. Patel,Eshan U. Patel,Evan M. Bloch,William Clarke,Yu Hsiang Hsieh,Denali Boon,Yolanda Eby,Reinaldo E Fernandez,Owen R Baker,Morgan Keruly,Charles S. Kirby,Ethan Klock,Kirsten Littlefield,Jernelle Miller,Haley A Schmidt,Philip Sullivan,Estelle Piwowar-Manning,Ruchee Shrestha,Andrew D. Redd,Andrew D. Redd,Richard E. Rothman,David Sullivan,Shmuel Shoham,Arturo Casadevall,Thomas C. Quinn,Thomas C. Quinn,Andrew Pekosz,Aaron A.R. Tobian,Oliver Laeyendecker,Oliver Laeyendecker +29 more
TL;DR: The diagnostic accuracy of five commercially available EIAs (Abbott, Euroimmun, EDI, ImmunoDiagnostics, and Roche) for detection of IgG or total antibodies to SARS-CoV-2 and neutralizing antibodies (nAbs) was evaluated.
Journal ArticleDOI
SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Sarah E. Benner,Eshan U. Patel,Oliver Laeyendecker,Oliver Laeyendecker,Andrew Pekosz,Kirsten Littlefield,Yolanda Eby,Reinaldo E Fernandez,Jernelle Miller,Charles S Kirby,Morgan Keruly,Ethan Klock,Owen R Baker,Haley A Schmidt,Ruchee Shrestha,Imani Burgess,Tania S. Bonny,William Clarke,Patrizio Caturegli,David J. Sullivan,Shmuel Shoham,Thomas C. Quinn,Thomas C. Quinn,Evan M. Bloch,Arturo Casadevall,Aaron A.R. Tobian,Andrew D. Redd,Andrew D. Redd +27 more
TL;DR: SARS-CoV-2 antibody avidity correlated with duration of infection and higher neutralizing titers, suggesting a potential alternative screening parameter for identifying optimal convalescent plasma donors.
Posted ContentDOI
Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
Eshan U. Patel,Eshan U. Patel,Evan M. Bloch,William Clarke,Yu Hsiang Hsieh,Denali Boon,Yolanda Eby,Reinaldo E Fernandez,Owen R Baker,Morgan Keruly,Charles S. Kirby,Ethan Klock,Kirsten Littlefield,Jernelle Miller,Haley A Schmidt,Philip Sullivan,Estelle Piwowar-Manning,Ruchee Shrestha,Andrew D. Redd,Andrew D. Redd,Richard E. Rothman,David Sullivan,Shmuel Shoham,Arturo Casadevall,Thomas C. Quinn,Thomas C. Quinn,Andrew Pekosz,Aaron A.R. Tobian,Oliver Laeyendecker,Oliver Laeyendecker +29 more
TL;DR: Some but not all commercial EIAs may be useful in the identification of individuals with high nAbs in convalescent individuals, but did not necessarily have high diagnostic accuracy to detect high nabs.
Journal ArticleDOI
Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point of Care Testing.
Steven E. Conklin,Kathryn Martin,Yukari C. Manabe,Haley A Schmidt,Jernelle Miller,Morgan Keruly,Ethan Klock,Charles S Kirby,Owen R Baker,Reinaldo E Fernandez,Yolanda Eby,Justin Hardick,Kathryn Shaw-Saliba,Richard E. Rothman,Patrizio Caturegli,Andrew D. Redd,Andrew D. Redd,Aaron A.R. Tobian,Evan M. Bloch,H. Benjamin Larman,Thomas C. Quinn,Thomas C. Quinn,William Clarke,Oliver Laeyendecker,Oliver Laeyendecker +24 more
TL;DR: The timing of seroconversion was assessed using five lateral flow assays (LFAs) and a panel of 272 longitudinal samples from 47 patients for whom the time since symptom onset was known, and the IgM band was the band most likely to mis classify prepandemic samples.
Journal ArticleDOI
GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers.
John P. Gustin,Jernelle Miller,Mina Farag,D. Marc Rosen,Matthew C. Thomas,Robert B. Scharpf,Josh Lauring +6 more
TL;DR: GATA3 mutation enhanced tumor growth in vivo but did not affect sensitivity to clinically used hormonal therapies or chemotherapeutic agents, and genes with upregulated and downregulated expression in GATA3 mutant cells were identified.